• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

Stock

The stock will go > $90 again, just not sustainably for at least the next 12-18 months. We're range-bound < $100 and > $70, with a bias to the downside.

Next year, the dividend will remain flat to a lower than avg increase. There are a number of headwinds beyond what you mentioned that will impact institutional interest in the company. Those include but are not limited to 1) failing to close strategic divestments that would have optimized the balance sheet, 2) missing sales growth targets from recent and future launches and 3) a narrowing margin expansion from an exhausted productivity improvement program.

> $90 briefly today. A potentially interesting set-up for a re-test of the all-time highs > $
100 just before next week's earnings announcement. However, risk/reward remains limited under current market conditions. $70 target minimum by end July.
 




> $90 briefly today. A potentially interesting set-up for a re-test of the all-time highs > $
100 just before next week's earnings announcement. However, risk/reward remains limited under current market conditions. $70 target minimum by end July.

Without all the stim injections into the financial plumbing system in the last quarter, this stock would be in the 60s. Even still, the price is barely holding $80.
 




Similar threads

Replies
1
Views
634
Novartis
anonymous
Replies
27
Views
6K
Replies
22
Views
3K
Novartis
anonymous